Cardiovascular disease: risk assessment and reduction, including lipid modification

inform discussions about primary prevention of CVD. [May 2023, amended December 2023] 1.11.11 During the annual medication review: • discuss and encourage medicines adherence, if the shared decision is to continue with lipid-lowering treatment • discuss and encourage dietary and lifestyle changes if appropriate • address CVD risk factors. [May 2023, amended December 2023] 1.11.12 Discuss with people who are stable on a low-intensity statin or medium-intensity statin the likely benefits and potential risks of changing to a high-intensity statin when they have a medication review and agree with the person whether a change is needed. [May 2023] For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on assessing response to treatment. Full details of the evidence and the committee's discussion are in evidence review C: statins: efficacy and adverse effects. 1.12 Lipid-lowering treatments that should not be used or not used routinely These recommendations apply to primary and secondary prevention of CVD, including people with diabetes and CKD. They do not apply to people with familial hypercholesterolaemia. For guidance on using fibrates, bile acid sequestrants and combination treatment for this population group, follow the recommendations
